News | April 01, 2022
Evonik restructures health care business
The new structure further transitions the Health Care business line into a system solutions partner for the pharmaceutical and biotech industries
The new structure further transitions the Health Care business line into a system solutions partner for the pharmaceutical and biotech industries
Adds to Merck’s growing global, multi-modality CDMO network, following newly formed CDMO business unit in Life Science
Simulated Moving Bed (SMB) technology is a highly engineered process for implementing chromatographic separation
The transaction is expected to close in the first quarter of 2022
Merck forecasts organic growth of EBITDA pre in a high single-digit to low teens percentage range in 2021.
Subscribe To Our Newsletter & Stay Updated
